We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Performance of newer myeloma staging systems in a contemporary, large patient cohort.
- Authors
Mohyuddin, Ghulam Rehman; Rubinstein, Samuel M.; Kumar, Shaji; Rajkumar, S. Vincent; Fonseca, Rafael; Abdallah, Nadine H.; Calip, Gregory S.; Wang, Xiaoyan; Parrinello, Christina M.; Sborov, Douglas
- Abstract
This letter discusses the performance of newer staging systems for multiple myeloma (MM) in a large cohort of patients. The Revised International Staging System (R-ISS), the most widely used staging system, does not account for certain risk factors. Two new staging systems, the Mayo Additive Staging System (MASS) and the Second Revision of the International Staging System (R2-ISS), have been proposed to address these limitations. The study validates MASS and R2-ISS and compares their performance to R-ISS. The results show that both MASS and R2-ISS perform similarly to R-ISS and provide more refined risk stratification for patients. However, the performance of all three staging systems remains suboptimal. Further validation is needed with longer follow-up and more use of quadruplet therapy.
- Subjects
MULTIPLE myeloma; KAPLAN-Meier estimator; CLINICAL trials; MONOCLONAL gammopathies
- Publication
Blood Cancer Journal, 2024, Vol 14, Issue 1, p1
- ISSN
2044-5385
- Publication type
Article
- DOI
10.1038/s41408-024-01076-w